Critical appraisal of the SIBO hypothesis and breath testing: A clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility society (ANMS).
bloating
disorders of gut‐brain interaction
irritable bowel syndrome
lactulose hydrogen breath test
microbiome
small intestinal bacterial overgrowth
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
26 May 2024
26 May 2024
Historique:
revised:
30
04
2024
received:
20
11
2023
accepted:
03
05
2024
medline:
27
5
2024
pubmed:
27
5
2024
entrez:
27
5
2024
Statut:
aheadofprint
Résumé
There is compelling evidence that microbe-host interactions in the intestinal tract underlie many human disorders, including disorders of gut-brain interactions (previously termed functional bowel disorders), such as irritable bowel syndrome (IBS). Small intestinal bacterial overgrowth (SIBO) has been recognized for over a century in patients with predisposing conditions causing intestinal stasis, such as surgical alteration of the small bowel or chronic diseases, including scleroderma and is associated with diarrhea and signs of malabsorption. Over 20 years ago, it was hypothesized that increased numbers of small intestine bacteria might also account for symptoms in the absence of malabsorption in IBS and related disorders. This SIBO-IBS hypothesis stimulated significant research and helped focus the profession's attention on the importance of microbe-host interactions as a potential pathophysiological mechanism in IBS. However, after two decades, this hypothesis remains unproven. Moreover, it has led to serious unintended consequences, namely the widespread use of unreliable and unvalidated breath tests as a diagnostic test for SIBO and a resultant injudicious use of antibiotics. In this review, we examine why the SIBO hypothesis remains unproven and, given the unintended consequences, discuss why it is time to reject this hypothesis and its reliance on breath testing. We also examine recent IBS studies of bacterial communities in the GI tract, their composition and functions, and their interactions with the host. While these studies provide important insights to guide future research, they highlight the need for further mechanistic studies of microbe-host interactions in IBS patients before we can understand their possible role in diagnosis and treatment of patient with IBS and related disorders.
Sections du résumé
BACKGROUND
BACKGROUND
There is compelling evidence that microbe-host interactions in the intestinal tract underlie many human disorders, including disorders of gut-brain interactions (previously termed functional bowel disorders), such as irritable bowel syndrome (IBS). Small intestinal bacterial overgrowth (SIBO) has been recognized for over a century in patients with predisposing conditions causing intestinal stasis, such as surgical alteration of the small bowel or chronic diseases, including scleroderma and is associated with diarrhea and signs of malabsorption. Over 20 years ago, it was hypothesized that increased numbers of small intestine bacteria might also account for symptoms in the absence of malabsorption in IBS and related disorders. This SIBO-IBS hypothesis stimulated significant research and helped focus the profession's attention on the importance of microbe-host interactions as a potential pathophysiological mechanism in IBS.
PURPOSE
OBJECTIVE
However, after two decades, this hypothesis remains unproven. Moreover, it has led to serious unintended consequences, namely the widespread use of unreliable and unvalidated breath tests as a diagnostic test for SIBO and a resultant injudicious use of antibiotics. In this review, we examine why the SIBO hypothesis remains unproven and, given the unintended consequences, discuss why it is time to reject this hypothesis and its reliance on breath testing. We also examine recent IBS studies of bacterial communities in the GI tract, their composition and functions, and their interactions with the host. While these studies provide important insights to guide future research, they highlight the need for further mechanistic studies of microbe-host interactions in IBS patients before we can understand their possible role in diagnosis and treatment of patient with IBS and related disorders.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14817Subventions
Organisme : NIH HHS
Pays : United States
Organisme : CIHR
Pays : Canada
Organisme : Atmo Biosciences
Organisme : 4D Pharma
Organisme : Takeda Pharmaceutical Company
Organisme : Cindome
Organisme : Vibrant
Informations de copyright
© 2024 The Author(s). Neurogastroenterology & Motility published by John Wiley & Sons Ltd.
Références
White WH. On the pathology and prognosis of pernicious anemia. Guys Hosp Rep. 1890;47:149.
Barker WH, Hummel LE. Macrocytic anemia in association with intestinal strictures and anastomoses: review of literature and report of 2 new cases. Bull Johns Hopkins Hosp. 1939;64:215‐256.
Card WI. Blind loop syndrome. Proc R Soc Med. 1959;52:28‐31.
Badenoch J. The blind loop syndrome. Proc R Soc Med. 1960;53:657‐658.
Donaldson RM Jr. Normal bacterial populations of the intestine and their relation to intestinal function. N Engl J Med. 1964;270:1050–6 concl:938‐945.
Neale G, Gompertz D, Schönsby H, Tabaqchali S, Booth CC. The metabolic and nutritional consequences of bacterial overgrowth in the small intestine. Am J Clin Nutr. 1972;25:1409‐1417.
Murphy MF, Sourial NA, Burman JF, Doyle DV, Tabaqchali S, Mollin DL. Megaloblastic anaemia due to vitamin B12 deficiency caused by small intestinal bacterial overgrowth: possible role of vitamin B12 analogues. Br J Haematol. 1986;62:7‐12.
Greenberger NJ, Saegh S, Ruppert RD. Urine indican excretion in malabsorptive disorders. Gastroenterology. 1968;55:204‐211.
Bushyhead D, Quigley EMM. Small intestinal bacterial overgrowth‐pathophysiology and its implications for definition and management. Gastroenterology. 2022;163:593‐607.
Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double‐blind, randomized, placebo‐controlled study. Am J Gastroenterol. 2003;98:412‐419.
Bond JH Jr, Levitt MD, Prentiss R. Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H2) measurements. J Lab Clin Med. 1975;85:546‐555.
Read NW, Al‐Janabi MN, Bates TE, et al. Interpretation of the breath hydrogen profile obtained after ingesting a solid meal containing unabsorbable carbohydrate. Gut. 1985;26:834‐842.
Miller MA, Parkman HP, Urbain JL, et al. Comparison of scintigraphy and lactulose breath hydrogen test for assessment of orocecal transit: lactulose accelerates small bowel transit. Dig Dis Sci. 1997;42:10‐18.
Keller J, Bassotti G, Clarke J, et al. Expert consensus document: advances in the diagnosis and classification of gastric and intestinal motility disorders. Nat Rev Gastroenterol Hepatol. 2018;15:291‐308.
Cann PA, Read NW, Brown C, Hobson N, Holdsworth CD. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut. 1983;24:405‐411.
Yu D, Cheeseman F, Vanner S. Combined oro‐caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro‐caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60:334‐340.
Ghoshal UC, Nehra A, Mathur A, Rai S. A meta‐analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome. J Gastroenterol Hepatol. 2020;35:922‐931.
Lin EC, Massey BT. Scintigraphy demonstrates high rate of false‐positive results from glucose breath tests for small bowel bacterial overgrowth. Clin Gastroenterol Hepatol. 2016;14:203‐208.
Sellin JH, Hart R. Glucose malabsorption associated with rapid intestinal transit. Am J Gastroenterol. 1992;87:584‐589.
Berean KJ, Ha N, Ou JZ, et al. The safety and sensitivity of a telemetric capsule to monitor gastrointestinal hydrogen production in vivo in healthy subjects: a pilot trial comparison to concurrent breath analysis. Aliment Pharmacol Ther. 2018;48:646‐654.
Sundin OH, Mendoza‐Ladd A, Morales E, et al. Does a glucose‐based hydrogen and methane breath test detect bacterial overgrowth in the jejunum? Neurogastroenterol Motil. 2018;30:e13350.
Massey BT, Wald A. Small intestinal bacterial overgrowth syndrome: a guide for the appropriate use of breath testing. Dig Dis Sci. 2021;66:338‐347.
Saffouri GB, Shields‐Cutler RR, Chen J, et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat Commun. 2019;10:2012.
Dervin H, Zarate‐Lopez N, Sweis R, et al. Low prevalence of positive hydrogen breath tests in patients with functional gastrointestinal conditions and hypermobile Ehlers‐Danlos syndrome. Neurogastroenterol Motil. 2023;35:e14570.
Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503‐3506.
Dridi B, Henry M, El Khéchine A, et al. High prevalence of Methanobrevibacter smithii and Methanosphaera stadtmanae detected in the human gut using an improved DNA detection protocol. PLoS One. 2009;4:e7063.
Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53:1443‐1454.
Collins BS, Lin HC. Double‐blind, placebo‐controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr. 2011;52:382‐386.
Tuteja AK, Talley NJ, Stoddard GJ, Verne GN. Double‐blind placebo‐controlled study of Rifaximin and lactulose hydrogen breath test in gulf war veterans with irritable bowel syndrome. Dig Dis Sci. 2019;64:838‐845.
Bae S, Lee KJ, Kim YS, Kim KN. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects. J Korean Med Sci. 2015;30:757‐762.
Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557‐563.
Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22‐32.
Rezaie A, Heimanson Z, McCallum R, Pimentel M. Lactulose breath testing as a predictor of response to Rifaximin in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2019;114:1886‐1893.
Sharara AI, Aoun E, Abdul‐Baki H, Mounzer R, Sidani S, ElHajj I. A randomized double‐blind placebo‐controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326‐333.
King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet. 1998;352:1187‐1189.
Dear KL, Elia M, Hunter JO. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Dig Dis Sci. 2005;50:758‐766.
Rao SS, Edwards CA, Austen CJ, et al. Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology. 1988;94:928‐932.
Di Stefano M, Mengoli C, Bergonzi M, et al. Hydrogen breath test in patients with severe constipation: the interference of the mixing of intestinal content. Neurogastroenterol Motil. 2014;26:1754‐1760.
Shah A, Talley NJ, Jones M, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta‐analysis of case‐control studies. Am J Gastroenterol. 2020;115:190‐201.
Takakura W, Wang JJ, Chey WD, Rezaie A, Pimentel M. Testing for small intestinal bacterial overgrowth provides a precision medicine approach to the treatment of irritable bowel syndrome: a systemic review and meta‐analysis. Gastroenterologia. 2022;162:S941.
Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta‐analysis. Clin Gastroenterol Hepatol. 2009;7:1279‐1286.
Shimura S, Ishimura N, Mikami H, et al. Small intestinal bacterial overgrowth in patients with refractory functional gastrointestinal disorders. J Neurogastroenterol Motil. 2016;22:60‐68.
Qing Y. Relationship betweeen the irritable bowel syndrome and small intestinal bacterial. J Gastroenterol Hepatol. 2013;28:375.
Chuah KH, Wong MS, Tan PO, et al. Small intestinal bacterial overgrowth in various functional gastrointestinal disorders: a case‐control study. Dig Dis Sci. 2022;67:3881‐3889.
Tziatzios G, Gkolfakis P, Papanikolaou IS, et al. High prevalence of small intestinal bacterial overgrowth among functional dyspepsia patients. Dig Dis. 2021;39:382‐390.
Salim B, Elriz K, Gourcerol G, Leroi AM, Ducrotté PR. S1342 effect of proton pump inhibitors on the results of glucose breath test. Gastroenterologia. 2010;138:S233.
Sosa OR, Amieva‐Balmori M, Galvez‐Rios S, et al. Tu1738 glucose breath test in patients with overlapping FD and IBS. Is there any difference compared to patients with only FD or only IBS? Gastroenterologia. 2016;150:S929‐S930.
Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8:504‐508.
Evans KE, Sanders DS. Celiac disease. Gastroenterol Clin North Am. 2012;41:639‐650.
Wanzl J, Gröhl K, Kafel A, et al. Impact of small intestinal bacterial overgrowth in patients with inflammatory bowel disease and other gastrointestinal disorders‐a retrospective analysis in a tertiary single center and review of the literature. J Clin Med. 2023;12:935.
Weitsman S, Celly S, Leite G, et al. Effects of proton pump inhibitors on the small bowel and stool microbiomes. Dig Dis Sci. 2022;67:224‐232.
Booth M, Hunt JN, Miles JM, et al. Comparison of gastric emptying and secretion in men and women with reference to prevalence of duodenal ulcer in each sex. Lancet. 1957;272:657‐659.
Talley NJ, Peterson KA, Genta RM, et al. High discovery rate of duodenal and gastric eosinophilia in patients with unexplained moderate‐severe abdominal symptoms: a prospective US multisite study. Gastroenterology. 2023;164:680‐683.
Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane‐based breath testing in gastrointestinal disorders: the north American consensus. Am J Gastroenterol. 2017;112:775‐784.
Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115:165‐178.
Hammer HF, Fox MR, Keller J, et al. European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, endoscopy and nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus. United European Gastroenterol J. 2022;10:15‐40.
Ghoshal UC, Sachdeva S, Ghoshal U, et al. Asian‐Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: an initiative of the Indian Neurogastroenterology and motility association. Indian J Gastroenterol. 2022;41:483‐507.
Quigley EMM, Murray JA, Pimentel M. AGA clinical practice update on small intestinal bacterial overgrowth: expert review. Gastroenterology. 2020;159:1526‐1532.
Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70:1214‐1240.
Moayyedi P, Andrews CN, MacQueen G, et al. Canadian Association of Gastroenterology clinical practice guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol. 2019;2:6‐29.
Carrasco‐Labra A, Lytvyn L, Falck‐Ytter Y, Surawicz CM, Chey WD. AGA technical review on the evaluation of functional diarrhea and diarrhea‐predominant irritable bowel syndrome in adults (IBS‐D). Gastroenterology. 2019;157:859‐880.
Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116:17‐44.
Tacchino RM. Bowel length: measurement, predictors, and impact on bariatric and metabolic surgery. Surg Obes Relat Dis. 2015;11:328‐334.
Wang Y, Xiong L, Gong X, Li W, Zhang X, Chen M. Small intestinal bacterial overgrowth as an uncommon cause of false positive lactose hydrogen breath test among patients with diarrhea‐predominant irritable bowel syndrome in Asia. J Gastroenterol Hepatol. 2015;30:995‐1000.
Camilleri M, Vassallo M. Small intestinal motility and transit in disease. Baillieres Clin Gastroenterol. 1991;5:431‐451.
Degen LP, Phillips SF. Variability of gastrointestinal transit in healthy women and men. Gut. 1996;39:299‐305.
Graff J, Brinch K, Madsen JL. Gastrointestinal mean transit times in young and middle‐aged healthy subjects. Clin Physiol. 2001;21:253‐259.
Worsøe J, Fynne L, Gregersen T, et al. Gastric transit and small intestinal transit time and motility assessed by a magnet tracking system. BMC Gastroenterol. 2011;11:145.
Delbaere K, Roegiers I, Bron A, et al. The small intestine: dining table of host‐microbiota meetings. FEMS Microbiol Rev. 2023;47:1‐32.
Agrawal S, Aoun E. Diseases of the Pancreas: The Physiology of the Pancreas. Practical Gastroenterology; 2014:48‐56.
Sheridan WG, Lowndes RH, Young HL. Intraoperative tissue oximetry in the human gastrointestinal tract. Am J Surg. 1990;159:314‐319.
Kastl AJ Jr, Terry NA, Albenberg LG, et al. The structure and function of the human small intestinal microbiota: current understanding and future directions. Cell Mol Gastroenterol Hepatol. 2019;9(1):33‐45.
Shalon D, Culver RN, Grembi JA, et al. Profiling the human intestinal environment under physiological conditions. Nature. 2023;617:581‐591.
Martinez‐Guryn K, Hubert N, Frazier K, et al. Small intestine microbiota regulate host digestive and absorptive adaptive responses to dietary lipids. Cell Host Microbe. 2018;23:458‐469.
Devkota S, Wang Y, Musch MW, et al. Dietary‐fat‐induced taurocholic acid promotes pathobiont expansion and colitis in Il10−/− mice. Nature. 2012;487:104‐108.
Zoetendal EG, Raes J, van den Bogert B, et al. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. ISME J. 2012;6:1415‐1426.
Kastl AJ Jr, Terry NA, Wu GD, Albenberg LG. The structure and function of the human small intestinal microbiota: current understanding and future directions. Cell Mol Gastroenterol Hepatol. 2020;9:33‐45.
Leite G, Rezaie A, Mathur R, et al. Defining small intestinal bacterial overgrowth by culture and high throughput sequencing. Clin Gastroenterol Hepatol. 2023;22:259‐270.
Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel syndrome: a gut microbiota‐related disorder? Am J Physiol Gastrointest Liver Physiol. 2017;312:G52‐G62.
Ou Y, Belzer C, Smidt H, de Weerth C. Methodological recommendations for human microbiota‐gut‐brain axis research. Microbiome Res Rep. 2024;3:1‐13.
Attar A, Flourié B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth‐related chronic diarrhea: a crossover, randomized trial. Gastroenterology. 1999;117:794‐797.
Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short‐term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14:551‐556.
Castiglione F, Rispo A, Di Girolamo E, et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther. 2003;18:1107‐1112.
Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose‐finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22:31‐35.
Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2‐glucose breath test. Curr Med Res Opin. 2000;16:14‐20.
Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25:781‐786.
Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci. 2007;333:266‐270.
Esposito I, de Leone A, Di Gregorio G, et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non‐absorbable antibiotics. World J Gastroenterol. 2007;13:6016‐6021.
Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139‐142.
Lauritano EC, Gabrielli M, Scarpellini E, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci. 2009;13:111‐116.
Furnari M, Parodi A, Gemignani L, et al. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2010;32:1000‐1006.
Rosania R, Giorgio F, Principi M, et al. Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. Curr Clin Pharmacol. 2013;8:169‐172.
Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2013;17:1314‐1320.
Tahan S, Melli LC, Mello CS, et al. Effectiveness of trimethoprim‐sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum. J Pediatr Gastroenterol Nutr. 2013;57:316‐318.
Ghoshal UC, Srivastava D, Misra A, Ghoshal U. A proof‐of‐concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small‐intestinal bacterial overgrowth: a randomized, double‐blind, placebo‐controlled trial. Eur J Gastroenterol Hepatol. 2016;28:281‐289.
García‐Collinot G, Madrigal‐Santillán EO, Martínez‐Bencomo MA, et al. Effectiveness of saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis. Dig Dis Sci. 2020;65:1134‐1143.
Zhuang X, Tian Z, Luo M, Xiong L. Short‐course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea‐predominant irritable bowel syndrome. BMC Gastroenterol. 2020;20:187.
Kim YJ, Jo IH, Paik CN, Lee JM. Efficacies of prokinetics and rifaximin on the positivity of a glucose breath test in patients with functional dyspepsia: a randomized trial. Rev Esp Enferm Dig. 2023;115:121‐127.